Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218.

Rebecca J DeyellBing WuS Rod RassekhDongsheng TuYvan SamsonAdam FlemingEric BouffetXiaoqun SunJean PowersLesley SeymourSylvain BaruchelDaniel A Morgenstern

Published in: Pediatric blood & cancer (2018)

The combination of weekly temsirolimus (15 mg/m2 ) and vinblastine (4 mg/m2 ) exceeds the maximum tolerated dose in children, with frequent oral mucositis and hematologic toxicity.

Keyphrases

papillary thyroid
young adults
oxidative stress
radiation induced
childhood cancer
radiation therapy
chemotherapy induced